(secondQuint)UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer.

 OBJECTIVES: - Determine the efficacy of UCN-01, in terms of time to objective progression, in patients with stage IV or unresectable stage III renal cell carcinoma.

 - Determine the objective response rate in patients treated with this drug.

 OUTLINE: Patients receive UCN-01 IV over 3 hours on day 1.

 Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

 PROJECTED ACCRUAL: A total of 21-61 patients will be accrued for this study within 15 months.

.

 UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer@highlight

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

 PURPOSE: Phase II trial to study the effectiveness of UCN-01 in treating patients who have unresectable stage III or stage IV kidney cancer.

